What is HC Wainwright’s Estimate for BHST FY2028 Earnings?

BioHarvest Sciences Inc. (NASDAQ:BHST) – Investment analysts at HC Wainwright reduced their FY2028 EPS estimates for BioHarvest Sciences in a research report issued to clients and investors on Friday, May 15th. HC Wainwright analyst A. Dayal now anticipates that the company will earn $0.26 per share for the year, down from their previous estimate of $0.36. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ FY2030 earnings at $1.50 EPS.

Other equities analysts have also issued reports about the stock. Roth Mkm assumed coverage on shares of BioHarvest Sciences in a research report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioHarvest Sciences currently has an average rating of “Hold” and a consensus price target of $10.00.

BioHarvest Sciences Price Performance

Shares of BHST opened at $4.10 on Monday. The firm has a market capitalization of $80.44 million, a PE ratio of -6.95 and a beta of 0.81. The company’s 50-day moving average is $4.26 and its 200-day moving average is $5.25. BioHarvest Sciences has a fifty-two week low of $3.57 and a fifty-two week high of $12.80. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.97 and a quick ratio of 3.38.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The company had revenue of $8.51 million for the quarter, compared to analyst estimates of $8.50 million. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 102.36%.

Hedge Funds Weigh In On BioHarvest Sciences

Several institutional investors and hedge funds have recently modified their holdings of BHST. King Luther Capital Management Corp acquired a new position in shares of BioHarvest Sciences in the fourth quarter valued at about $208,000. Geode Capital Management LLC acquired a new position in shares of BioHarvest Sciences in the fourth quarter valued at about $61,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of BioHarvest Sciences in the fourth quarter valued at about $1,945,000. HRT Financial LP acquired a new position in shares of BioHarvest Sciences in the fourth quarter valued at about $75,000. Finally, Jane Street Group LLC acquired a new position in shares of BioHarvest Sciences in the fourth quarter valued at about $145,000.

Trending Headlines about BioHarvest Sciences

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: First-quarter revenue rose 8% year over year to about $8.5 million, slightly ahead of estimates, while EPS matched expectations at a loss of $0.11 per share. BioHarvest Sciences earnings report
• Positive Sentiment: The company said its CDMO business grew 135% year over year in the quarter and highlighted progress on fragrance and saffron projects, which supports its growth narrative. BioHarvest Sciences Q1 2026 Financial Results and Business Update
• Positive Sentiment: Management reaffirmed full-year revenue guidance of $42 million to $48 million and separately outlined 2026 revenue expectations of $38 million to $42 million for direct-to-consumer and $12 million to $14 million for CDMO activity. Seeking Alpha revenue outlook article
• Neutral Sentiment: The company also said its VINIA brand customer base reached 90,000 active users by the end of April and that it is holding a conference call and filing Q1 financials, reinforcing the latest disclosure rather than introducing a new catalyst. BioHarvest Sciences files Q1 2026 financials
• Negative Sentiment: Despite revenue progress, BHST remains unprofitable, and management’s growth story may not be enough to offset concern over ongoing losses and negative margins in the near term. Zacks earnings recap

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.